What is intervention to counter too many red bloood cells

The short version: for polycythemia vera, the strongest evidence supports phlebotomy to a hematocrit below 45%, and the newer drugs mostly reduce how often you need it.

The standard first intervention is phlebotomy—removing blood until the hematocrit (the fraction of blood made of red cells) stays below 45%. The CYTO-PV trial showed this cut matters: patients kept below 45% had a thrombosis rate of 2.7% over 31 months, while those above it had 9.8%, a hazard ratio of about 3.9 [1]. That is a real, measured difference in a hard outcome (clots), not a surrogate. Phlebotomy is cheap, unpatented, and the evidence for it comes from a prospective trial, not from the manufacturer.

When phlebotomy alone is not enough, or the patient cannot tolerate it, the next step is usually hydroxyurea, a chemotherapy drug that suppresses bone marrow output. Real-world data shows it works poorly for many: in a chart review of over 1,000 patients on hydroxyurea, only 37% achieved complete blood count control, and 21% had no response at all [16]. Another study found hydroxyurea did not produce sustained normalization of white cell or platelet counts, and its effect on the JAK2 mutation driving the disease was only a transient 15% drop [20]. The drug is old, cheap, and the evidence for it is thin by modern standards.

Newer drugs aim to replace or reduce phlebotomy. Ruxolitinib (a JAK inhibitor) was tested against standard therapy in hydroxyurea-resistant patients: 60% achieved hematocrit control versus 20% on standard therapy, and 49% had a meaningful symptom reduction [12]. But the trial was funded by the manufacturer (Incyte), the primary endpoint was a composite of hematocrit control and spleen reduction (not thrombosis or death), and the drug costs thousands per month. Rusfertide (a hepcidin mimetic) in the REVIVE phase 2 trial cut annual phlebotomy from about 9 to less than 1, and 60% of patients maintained hematocrit control without phlebotomy during a withdrawal phase versus 17% on placebo [8]. Again, manufacturer-funded, phase 2, and the long-term safety data is not yet public.

My call: phlebotomy to a hematocrit below 45% is the only intervention with prospective trial evidence for a hard clinical benefit (fewer clots). The newer drugs reduce phlebotomy need and improve symptoms, but the evidence is manufacturer-funded, uses composite or surrogate endpoints, and lacks long-term safety data. Confidence: moderate for phlebotomy, low for the newer drugs.